A new study led by UNSW Sydney researchers demonstrates the feasibility and promise of the innovative XV Scanner™ with XV LVAS®, non-invasive imaging tools developed by 4DMedical, for assessing regional lung function in adults with bronchiectasis caused by Primary Ciliary Dyskinesia (PCD) and other conditions. In this ongoing trial across four Sydney hospitals, participants successfully underwent XV scans that provided detailed, real-time maps of ventilation across the lungs, revealing regional ventilation heterogeneity not detectable by standard global lung function tests. Notably, the XV-derived ventilation defect percentage significantly correlated with traditional spirometry measures, supporting XV analysis as a sensitive measure of regional lung impairment. These early results highlight the XV Scanner’s promise as a powerful tool for early detection and personalized management of bronchiectasis, with further recruitment underway to expand this important research.